Company Background

GeneFluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide health. By integrating novel bionano and microfluidic technologies, the company's platform enables complex tests that are normally performed only by skilled technicians in a laboratory to be performed by anyone, anywhere (1a).

Originally conceived as part of a biodefense program, the platform integrates nanotechnology-enabled analyte detection with microfluidic-based automated sample preparation for rapid and accurate 'plug and play' use. For system operation, the user simply introduces a raw sample such as whole blood, urine, saliva, or water to a disposable cartridge, inserts this cartridge into a reader instrument, pushes a button, and waits 10-20 minutes for test results (1a).

Suppliers and Buyers

GeneFluidics' sensor chip products are being non-exclusively distributed by Fisher Scientific (1d).

Strategic Partnerships

In a clinical study conducted by the David Geffen School of Medicine at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System, researchers used a biosensor developed by GeneFluidics to identify the infection-causing bacteria species found in 98 percent of the tested clinical urinary tract infection (the second most common bacterial infection) urine samples. The results represented the first species-specific detection of bacteria in human clinical fluid samples using a microfabricated electrochemical sensor array. Of equal significance, the new test provided results in 45 minutes, compared to two days with conventional methods. The research results were reported in the February 2006 issue of the peer-reviewed Journal of Clinical Microbiology (3). 

GeneFluidics and the Los Angeles and Palo Alto VA Hospitals are collaborating on the development of a rapid antibiotic suceptibility testing system. The project is funded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (1a).

GeneFluidics, Inc. and the Shanghai Institute of Applied Physics, Chinese Academy of Sciences have collaborated to develop nanoparticle-based electrochemical detection tools for cancer research and diagnosis. GeneFluidics’ non-amplified molecular analysis system enables the detection of analytes at the ultra-low quantities present at the early stages of disease. When coupled with novel tools developed by Shanghai Institute of Applied Physics, an integrated system could stimulate widespread biomarker monitoring for early cancer detection (2).

GeneFluidics and the Department of Dental and Oral Biology at UCLA are co-developing a point-of-care salivary diagnostics device, the first point-of-care device for head and neck cancer screening (1a).

Innovation and Technology

GeneFluidics’ sensor technology enables quantification of nucleic acids and proteins in unprocessed samples on a single platform. Their patented sensor fabrication and electrochemical detection methods provide high sensitivity even in unamplified, unpurified biological samples. Results are delivered within 1 hour (1c).


  • SC1000-16X - sensor chip: 16 independent assays can be performed
  • Helios : multi-channel electrochemical workstation,16 different electrochemical experiments can be performed simultaneously
  • Proteus Robotic System: designed to automate procedures that typically require extensive labor by skilled technicians
  • Asklepios system: consists of a self-contained, disposable microfluidic cartridge and a sensing and control instrument; the microfluidic cartridge integrates reagent storage and fluid-handling components along with the GeneFluidics sensor array to achieve ultra-sensitive, multiplexed detection (1b).

For more information, see the GeneFluidics location page.


  1. Genefluidics Inc. (2011).  Retrieved on October 27, 2012
    1. “About Us” from
    2. “Products” from
    3. “Technology” from
    4. "About Us - Distribution" from
  2. Genefluidics Inc. (2005 August 8). “GeneFluidics, Inc. Announces Collaboration with the Shanghai Institute of Applied Physics, Chinese Academy of Sciences.” Retrieved on October 27, 2012 from
  3. Genefluidics Inc. (2006, February 2). “UCLA/VA Study Demonstrates the Rapid Diagnosis of Urinary Tract Infections With Novel Biosensor Technology.” Retrieved on October 27, 2012 from